20-year survival after radical prostatectomy as initial treatment for cT3 prostate cancer

BJU International

Volumn 110, Issue 11, 2012, Pages 1709-1713

  Mitchell, Christopher R ^a   Boorjian, Stephen A ^a   Umbreit, Eric C ^a   Rangel, Laureano J ^a   Carlson, Rachel E ^a   Karnes, R Jeffrey ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

clinical T3; extraprostatic extension; prostate cancer; radical prostatectomy; seminal vesicle invasion

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER INVASION; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; FOLLOW UP; GLEASON SCORE; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; NONDIPLOID CHROMATIN CONTENT; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; POSITIVE SURGICAL MARGIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE;

EID: 84870900143     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11372.x     Document Type: Article

References (21)

1. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H,. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005; 95: 751-6
2. Meng MV, Elkin EP, Latini DM, Duchane J, Carroll PR,. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol 2005; 173: 1557-61
3. Meltzer D, Egleston B, Abdalla I,. Patterns of prostate cancer treatment by clinical stage and age. Am J Public Health 2001; 91: 126-8
4. Bolla M, Collette L, Blank L, et al,. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-6
5. Bolla M, Laramas M, on behalf of AROME. Combined hormone therapy and radiation therapy for locally advanced prostate cancer. Crit Rev Oncol Hematol 2010; [Epub ahead of print]. DOI:10.1016/j.critrevonc.2010.11.003
6. Carver BS, Bianco FJ Jr, Scardino PT, Eastham JA,. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 2006; 176: 564-8
7. Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC,. Radical prostatectomy for clinical stage T3a disease. Cancer 2007; 109: 1273-8
8. Loeb S, Smith ND, Roehl KA, Catalona WJ,. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 2007; 69: 1170-5
9. Bostwick DG, Myers RP, Oesterling JE,. Staging of prostate cancer. Semin Surg Oncol 1994; 10: 60-72
10. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H,. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000; 164: 101-5
11. Stephenson AJ, Kattan MW, Eastham JA, et al,. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006; 24: 3973-8
12. Keating NL, O'Malley AJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-56
13. Sanda MG, Dunn RL, Michalski J, et al,. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358: 1250-61
14. Nguyen PL, Je Y, Schutz FA, et al,. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011; 306: 2359-66
15. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV,. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009; 302: 866-73
16. Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H,. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 2007; 51: 121-9
17. Van der Poel HG, Moonen L, Horenblas S,. Sequential treatment for recurrent localized prostate cancer. J Surg Oncol 2008; 97: 377-82
18. Zelefsky MJ, Eastham JA, Cronin AM, et al,. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 2010; 28: 1508-13
19. Boorjian SA, Karnes RJ, Viterbo R, et al,. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 2011; 117: 2883-91
20. Xylinas E, Yates DR, Renard-Penna R, et al,. Role of pelvic phased array magnetic resonance imaging in staging of prostate cancer specifically in patients diagnosed with clinically locally advanced tumours by digital rectal examination. World J Urol 2011; [Epub ahead of print]. DOI: 10.1007/s00345-011- 0811-z
21. Ruprecht O, Weisser P, Bodelle B, Ackermann H, Vogl TJ,. MRI of the prostate: interobserver agreement compared with histopathologic outcome after radical prostatectomy. Eur J Radiol 2012; 81: 456-60